MICRONUTRIENT CUTANEOUSLY VITAMINS AND MINERALS MICRO ENCAPSULATED ON A TISSUE SUPPORT [...] GELLED WITH WATER-SOLUBLE EXCIPIENT AND A DEMULCENT

Dispositif pour une micro nutrition locale sous l'hypoderme en vitamine C, vitamines K, vitamine E, vitamine B3, vitamine B6, vitamine D, les minéraux Calcium, Magnésium, Cuivre, Fer ainsi que leurs dérivés micro encapsulés caractérisé par un tissu déperlant et un excipient hydrosoluble gélifié et émollient.

INSULATION PACKET

Un paquet (1) comprenant de la laine de fibres minérales d'isolation à souffler à l'état comprimé tenu par au moins un élément rétenteur est configuré pour avoir une expansion substantiellement le long d'un axe unique d'expansion lors du relâchement des éléments rétenteurs.

Controlled-Release CNS Modulating Compositions and Methods for the Treatment of Otic Disorders

Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).

Anode assembly, system including the assembly, and method of using same

The present invention relates to an anode assembly for use in an electrolytic cell for recovery of metal. The assembly includes a hanger bar, a first perimeter bar, a second perimeter bar, optionally one or more center conductor bars, a base bar, a first tab coupled to the first perimeter bar and/or the base bar, and a second tab coupled to the second perimeter bar and/or the base bar. The assembly may also include insulating separators coupled to the tabs and/or insulators coupled to an active area of the anode assembly. A system includes the anode assembly, a cathode assembly, and a tank.

LIPOSUCTION OF VISCERAL FAT USING TISSUE LIQUEFACTION

Visceral fat may be removed from a subject using a cannula that has an interior cavity and an orifice configured to permit material to enter the cavity. This is accomplished by generating a negative pressure in the cavity so that a portion of the tissue is drawn into the orifice. Fluid is then delivered in pulses, via a conduit, so that the fluid exits the conduit within the cavity and impinges against the portion of the tissue that was drawn into the orifice. The fluid is delivered at a pressure and temperature that causes the visceral fat to soften, liquefy, or gellify, without damaging the subject's internal organs that are in the vicinity of the visceral fat. The visceral fat that has been softened, liquefied, or gellified is then suctioned away. 1. A method of removing visceral fat from a live subject using a cannula that has a longitudinal axis that runs in a proximal-to-distal direction , the cannula having an interior cavity and an orifice that is configured to permit material to enter the interior cavity , the method comprising the steps of:generating a negative pressure in the interior cavity so that the negative pressure suctions visceral fat into the interior cavity via the orifice in a direction that is perpendicular to the longitudinal axis, wherein the orifice is substantially parallel to the longitudinal axis;impinging a series of pulses of fluid against the visceral fat that has been suctioned into the interior cavity, so that the visceral fat is softened, liquefied, or gellified; andsuctioning away, via the interior cavity, at least part of the fluid and at least part of the softened, liquefied, or gellified visceral fat.2. The method of claim 1 , wherein the pulses of fluid are impinged against the visceral fat at a pressure between 600 and 1300 psi and at a temperature between 100° F. and 140° F.3. The method of claim 2 , wherein the pulses of fluid are impinged against the visceral fat at a pulse rate of between 25 and 60 pulses per second.4. ...

Treatment of osteoarthritis

Provided are compositions and methods for treating osteoarthritis including intra-articular administration of a compound of Formula (I) including amorphous and polymorph forms thereof.

Integrated Automation of Paint Processes Incorporating Arrayed Painting and Inkjet Printing

A method of treating a tubular surface which defines an axis extending from a first surface end to a second surface end includes partially surrounding the tubular surface, at a first position, with a first set of treating units, with the treating units arranged in a first arcuate array. Furthermore, each treating unit is configured to include a plurality of first applicator heads. Additionally, an embodiment of the method includes determining a position of each of the plurality of first applicator heads relative to the tubular surface and moving the first set of treating units from the first position towards a second position. In one non-limiting example, the method further includes independently controlling each of the plurality of first applicator heads to selectively apply a first treatment as the first set of treating units moves from the first position towards the second position.

Phospholipid-based powders for drug delivery

Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.

Controlled release compositions for modulating free-radical induced damage and methods of use thereof

Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with free-radical modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Controlled release antimicrobial compositions and methods for the treatment of otic disorders

Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Systems and methods for the treatment of hemoglobinopathies

Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.

Private Health Insurance Exchange System and Method

Systems and methods for the distribution, equalization and mitigation of risks in an insurance exchange, and specifically to that of a private health insurance exchange system and method that rewards/punishes those attempting to poach or game it. The system and method also includes a way to create an insurance exchange so that those providers participating may get all or a fraction of any losses that exceed pre-established limits reimbursed to them as part of a payment by those providers participating in the exchange who received gains exceeding their expectations.

Syringe having a piston with embedded rfid chip

Although injection molding includes extreme conditions, an RFID device may be over-molded by injection molding. A syringe includes a barrel having a first and second axial ends, the barrel defining a cavity therein; a plunger configured to be received in the cavity and define with the barrel a chamber for holding a fluid, the plunger being axially moveable within the barrel for increasing and decreasing the volume of the chamber thereby respectively forcing fluid into or out of the chamber; and a plunger seal, also known as a “syringe stopper” for sealing between the plunger and the barrel, the plunger seal including an RFID device for identifying the syringe. The plunger seal may be made by injection molding.

Crispr/cas-related methods and compositions for treating beta hemoglobinopathies

CRISPR/CAS-related compositions and methods for treatment of beta hemoglobinopathies are disclosed.

Methods and systems for the electrochemical reduction of carbon dioxide using switchable polarity materials

A method of electrochemically reducing CO 2 comprises introducing a first feed stream comprising H 2 O to a positive electrode of an electrolysis cell comprising the positive electrode, a negative electrode, and a proton conducting membrane. A second feed stream comprising a solvent and a non polar form of a switchable polarity material is directed into a CO 2 capture apparatus. A third feed stream comprising CO 2 is directed into the CO 2 capture apparatus to interact with the second feed stream and form a first product stream comprising the solvent and a polar form of the switchable polarity material. The first product stream is introduced to the negative electrode. A potential difference is applied between the positive electrode and the negative electrode to convert the polar form of the switchable polarity material into CO 2 and the non-polar form and to form products from the CO 2 and the solvent. A CO 2 treatment system is also described.

Polyolefin compositions for films

The present disclosure provides polyolefin compositions and films and methods for producing such films. The polyolefin composition contains about 40 wt% to about 95 wt% of broad orthogonal composition distribution (BOCD) polyethylene and about 5 wt% to about 60 wt% of a polypropylene, by weight of the polyolefin composition. The polyolefin composition has a 1% secant flexural modulus in the machine direction (MD) of greater than 200 MPa and a 1% secant flexural modulus in the transverse direction (TD) of greater than 200 MPa, and a Tensile at Yield strength in the MD of greater than 8.5 MPa and a Tensile at Yield strength in the TD of greater than 9.7 MPa.

Controlled release corticosteroid compositions and methods for the treatment of otic disorders

Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase ("ATPase") modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Cytotoxicity mediation of cells evidencing surface expression of TROP-2

This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

Auris formulations for treating otic diseases and conditions

Single-dose, ready-to-use injectable formulations

Provided are single-dose, ready-to-use formulations and methods for preparing the formulations that include a compound of Formula (I) including pharmaceutically acceptable salts and amorphous and polymorph forms thereof.

Integrated medication delivery system

Automatic audio transducer adjustments based upon orientation of a mobile communication device

A solution for automatically activating different audio transducers of a mobile communication device based upon an orientation of the device. In the solution, a series of speaker/microphone assemblies can be positioned on the device, such as positioned near an earpiece and positioned near a mouthpiece. Different speaker/microphone assemblies can also be positioned on the front of the device and on the back of the device. The solution can automatically determine an orientation for the device, based upon a detected direction of a speech emitting source and/or based upon one or more sensors, such as a tilt sensor and an accelerometer. For example, when a device is in an upside down orientation, an earpiece microphone and a mouthpiece speaker can be activated. In another example, an otherwise deactivated rear facing speaker can be activated when the device is oriented in a rear facing orientation.

Low odor and volatiles polyolefin compositions and methods of production

Disclosed are compositions comprising at least one polyolefin, a hindered phenol, and a phenyl phosphite; wherein the overall concentration of the hindered phenol and phenyl phosphite is within a range from 10 ppm to 5000 ppm in the polyolefin, and wherein the amount of the hindered phenol is less than the phenyl phosphite. Also disclosed herein are compositions comprising at least one polypropylene, a neutralizer, a hindered phenol, and a phenyl phosphite; wherein the overall concentration of the hindered phenol and phenyl phosphite is within a range from 1000 ppm to 5000 ppm in the polyolefin, and wherein the amount of the hindered phenol is from 200 to 2000 ppm less than the phenyl phosphite.

Laser illuminated projection displays

A projection video display includes at least one laser for delivering a light beam. The display includes a beam homogenizer and a condenser lens. A scanning arrangement is provided for scanning the light in beam in a particular pattern over the condenser lens in a manner that effectively increases the beam divergence. The scanned beam is homogenized by a beam homogenizer and a spatial light modulator is arranged to receive the homogenized scanned light beam and spatially modulate the beam in accordance with a component of an image to be displayed. Projection optics are projecting the homogenized scanned light beam onto a screen. The scanning provides that the homogenized scanned light beam at the screen has a coherence radius less than the original coherence radius of the beam. The reduced coherence radius contributes to minimizing speckle contrast in the image displayed on the screen. The screen includes one or more features providing a further contribution to minimizing speckle contrast in the displayed image. In one example, the screen includes a transparent cell containing a liquid having light scattering particles in suspension.

Process for producing a non-woven fabric

A process for producing a nonwoven fabric comprising forming a polymer composition comprising a primary polypropylene and at least one secondary polyolefin; in a spunbond process, forming fibers then fabric from the polymer composition; and exposing the fabric to an heating environment within a range from 50° C. to 250° C.

Mode-locked laser

Mode-locked pulsed output is induced in a laser by introducing a varying frequency dependent loss in the cavity. The varying, frequency dependent loss allows a large number of longitudinal modes to oscillate. In one of the preferred embodiments of the subject invention, the varying frequency dependent loss is generated by reciprocating one of the mirrors of the resonator. In this embodiment, the laser has a resonator with a primary light path defined by first and second end mirrors. A gain medium is located between the end mirrors. A beam splitter is provided for redirecting the light into a secondary light path. A third mirror functions to feed back the light into the primary light path. Pulse formation is induced by varying the path length of one of the two paths by reciprocating an end mirror. Moving the mirror creates varying interference effects when the light energy is recombined at the beam splitter. The mirror is reciprocated relatively slowly, yet ultra-short pulses are generated.

Hydrocarbon oil/fluorochemical preparations and methods of use

Novel hydrocarbon oil/fluorochemical preparations and methods for their use are provided. The preparations, which preferably comprise a fluorophilic dispersing agent, may be in the form of hydrocarbon oil-in-fluorochemical dispersions or in the form of a multiple emulsion comprising a polar liquid continuous phase and are particularly useful for administering bioactive agents. In particular the preparations of the present invention may be used to control the bioavailability and improve the efficacy of lipophilic bioactive agents having limited solubility in an aqueous physiological environment.

Polypropylene nonwoven fibers, fabrics and methods for making same

Stabilized bioactive preparations and methods of use

Stabilized dispersions are provided for the delivery of a bioactive agent. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a liquid fluorochemical. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as by settling or flocculation. In particularly preferred embodiments the stabilized dispersions may be directly administered to the lung of a patient using an endotracheal tube or bronchoscope.

Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use

Microparticle compositions comprising metal ion-lipid complexes for drug delivery are described including methods of making the microparticle compositions and methods of treating certain conditions and disease states by administering the microparticle compositions. The metal ion-lipid complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle compositions of the present invention have superior stability to other microparticle compositions resulting in a microparticle composition with longer shelf life and improved dispersability. The microparticle compositions of the present invention have a transition temperature T m of at least 20° C. above the recommended storage temperature (Tst) for drug delivery.

Methods and compositions for delivering macromolecules to or via the respiratory tract

Methods and compositions for delivering macromolecules to or via the respiratory tract, such that the macromolecules exhibit improved local and/or systemic bioavailability are provided. Such methods utilize lipid-based microstructures formed in combination with at least one bioactive macromolecule, which have a superior ability to rapidly release the bioactive macromolecule(s) thereby resulting in improved local and/or systemic bioavailability of the bioactive macromolecule(s). Such improved bioavailability is believed to be due, in part, to reduction of scavenging by bronchoalveolar macrophages and/or mucociliary clearance. Compositions with improved bioavailability are provided comprising a plurality of lipid-based microstructures formed in combination with at least one bioactive macromolecule, wherein the bioavailability of the bioactive macromolecule is improved by modifying the rate of release of the bioactive macromolecule from the microstructure thereby reducing scavenging by bronchoalveolar macrophages and/or mucociliary clearance.

Reverse fluorocarbon emulsion compositions for drug delivery

A polar liquid-in-perfluorochemical emulsion or microemulsion for use in delivery of therapeutic or diagnostic agents. These compositions are formed by combining a discontinuous aqueous phase, a continuous fluorocarbon phase and a nonfluorinated surfactant. Further, the polar liquid-in-fluorochemical emulsions may be used to form multiple emulsions having an aqueous continuous phase. Such emulsions and microemulsions are suitable for the administration of pharmaceutical agents including genetic material.

Novel antibodies directed to the mammalian eag1 ion channel protein

The present invention relates to a particularly advantageous antibody, antibody fragment or derivative thereof, which specifically binds to/interacts with at least one epitope of the extracellular or intracellular domain of the mammalian EAG1 ion channel and to nucleic acid molecules encoding the same and to vectors comprising said nucleic acid molecules. The invention additionally relates to methods for the preparation of said antibody, antibody fragments or derivatives thereof and to pharmaceutical compositions comprising the same. Furthermore, the use of said antibody, antibody fragment or derivative thereof and also diagnostic compositions comprising said components are disclosed in the specification. The invention also relates to a method of assessing for the presence of EAG1 expressing cells and for a method of blocking EAG1 function in said cells. The invention further relates to a method of treating diseases with the help of said antibody or antibody fragment or derivative thereof.

Well filter with external shunts and manifold shunt connections at pipe joints

Mode-locked laser using non-linear self-focusing element

A passively mode-locked laser (110) is disclosed that includes a resonant cavity (112, 114) having a gain medium (116) therein. A transmissive element (116), which may be the gain medium, is also located in the cavity and is formed from a material which varies the two-dimensional, lateral spatial profile of the beam with respect to intensity due to the Kerr effect. The resonator is arranged such that the round trip gain of the system increases with respect to the intensity of the beam so that mode-locking operation can be achieved. In one approach, the variation in the spatial profile is used to increase the extraction of energy from the gain medium. In another approach, the variation in spatial profile which occurs with an increase in intensity is used to decrease the loss in the system so that pulse operation is favored. In an illustrated embodiment, wherein the gain medium (116) is formed from titanium-sapphire, the self-phase modulation of the crystal is also used to compress the pulses into the femtosecond range. In addition, a prism set (136, 138) can be used to balance the group velocity dispersion and self-phase modulation of the gain crystal to achieve stable, soliton-like operation. In the preferred embodiment, mode-locking behavior is initiating by rotating a transmissive optical element (230, 232) located in the cavity in a manner to vary the path length of the beam.

Treatment of osteoarthritis

Provided are compositions and methods for treating osteoarthritis including intra-articular administration of a compound of Formula (I) including amorphous and polymorph forms thereof.

Single-dose, ready-to-use injectable formulations

Provided are single-dose, ready-to-use formulations and methods for preparing the formulations that include a compound of Formula (I) including pharmaceutically acceptable salts and amorphous and polymorph forms thereof.

Treatment of osteoarthritis

Provided are compositions and methods for treating osteoarthritis including intra-articular administration of a compound of Formula (I) including amorphous and polymorph forms thereof.

2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof

Indazole compounds for treating various diseases and pathologies are provided. More particularly, the use of an indazole compound or analogs thereof, in the treatment of inflammatory diseases or disorders is provided.

Single-dose, ready-to-use injectable formulations

Provided are single-dose, ready-to-use formulations and methods for preparing the formulations that include a compound of Formula (I) including pharmaceutically acceptable salts and amorphous and polymorph forms thereof.

Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents

A method for preparing a pharmaceutical microdispersion exhibiting enhanced bioavailability, including the steps of providing a thermodynamically stable pharmaceutical composition comprising at least one lipophilic pharmaceutical agent incorporated in a physiologically acceptable liquid carrier, the liquid carrier comprising one or more lipophilic solvents such as fluorochemicals and preferably at least one nonfluorinated co-solvent, and combining the stable pharmaceutical composition with an amount of at least one miscible diluent sufficient to initiate phase separation of the lipophilic pharmaceutical agent from the pharmaceutical composition wherein a microdispersion of the pharmaceutical composition is formed. Also disclosed are microdisperse pharmaceutical compositions and kits for forming such compositions.

Verifying a slider tray map

A hard disk drive manufacture process may use a database to track the sliders stored within a slider tray. Instead of requiring an operator to visually inspect each tray to confirm that the database information is accurate, the trays may be sent to a detection system that uses a computer vision technique to identify the total number of sliders in a tray. In one embodiment, the computer vision technique may also determine where the sliders are stored in the slider tray—e.g., a particular row and column. If the information obtained using the computer vision technique differs from the information stored in the database, the system may perform one or more actions for correcting the discrepancy. In this manner, the computer vision technique may be used to update and confirm the slider tracking information stored in the database.

Cytotoxicity mediation of cells evidencing surface expression of CD63

This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.

Cytotoxicity mediation of cells evidencing surface expression of CD59

This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma

A monoclonal anti-CD44 antibody, or antigen-binding fragment thereof, for use in the treatment of a head and neck squamous cell carcinoma (HNSCC) in a mammal, wherein said HNSCC is characterized by the expression of CD44. Said monoclonal antibody may be produced by the hybridoma deposited with the ATCC with the accession number PTA-4621, and may be chimeric or humanized versions thereof.

Stent for use in a stent graft

A stent-graft for insertion into a body lumen, such as a blood vessel, is utilized in order to repair such lumen. The stent-graft includes a substantially cylindrical hollow expandable stent comprising a plurality of interconnected struts. The stent has a distal end and a proximal end, and an interior surface and an exterior surface. At least one strut of the stent has first and second apertures extending therethrough from the interior surface to the exterior surface. The stent-graft also includes a graft member covering a predetermined portion of least one of the interior surface and the exterior surface of the stent. In addition, the stent-graft further includes a staple for attaching the graft member to the stent. The staple has a crown and two legs extending therefrom. At least one of the legs of the staple extends through the graft material and through the first aperture. Both of the legs are bent inwardly towards said crown such that they evert back and extend through the second aperture.

Self-expanding stent-graft

In accordance with the present invention, there is provided a stent-graft for insertion into target site within a vessel of a patient. The graft has a crimped state for delivery to the target site, and an expanded state for implantation therein. The graft has a self-expanding outer stent, which is a tubular member made from an elastic material. The graft further includes a tubular flexible porous graft member extending along the interior of the outer stent. The graft member has front and back ends which are folded over and bonded to the front and back ends of the outer stent to form cuffs. In addition, the stent-graft has a self-expanding inner stent which also is a tubular member made from an elastic material. The inner stent is disposed within the interior of the graft member such that the inner stent, the graft member and the outer stent are all abutting.

Method for making a self-expanding stent-graft

In accordance with the present invention, there is provided a method of making a stent-graft for insertion into target site within a vessel of a patient. The graft has a crimped state for delivery to the target site, and an expanded state for implantation therein. The method uses a self-expanding tubular elastic outer stent having a crimped and expanded state, and includes the step of expanding the outer stent to its expanded state. The method also uses a tubular flexible porous graft member and includes the step of inserting the graft member along an interior of the outer stent. The method also uses a self-expanding tubular elastic inner stent, and includes the step of crimping the outer stent to a diameter smaller than a diameter of the expanded outer stent. The method then continues by inserting the inner stent within an interior of the graft member, and expanding the inner stent such that the inner stent, the graft member and the outer stent are all abutting.

G protein-coupled receptors

The present invention provides a gene encoding a G protein-coupled receptor termed nGPCR-x; constructs and recombinant host cells incorporating the genes; the nGPCR-x polypeptides encoded by the gene; antibodies to the nGPCR-x polypeptides; and methods of making and using all of the foregoing.

"USE OF AN ANTIBACTERIAL COMPOUND DERIVED FROM ALLIACEAS, AS ANIMAL FOOD ADDITIVES".

Utilización de un compuesto antibacteriano derivado de Alliaceas , como aditivo en alimentación animal, destinados como agente antimicrobiano en alimentación animal, y como alternativa, por su carácter antibacteriano, al uso de antibióticos como promotores del crecimiento, posponiéndose el uso tanto del compuesto de forma aislada (pureza superior al 95%), como encapsulado o soportado sobre diferentes materiales inertes o recubrimientos alimentarios, y porque dicho compuesto consiste, preferentemente en propiltiosulfinato de propilo y, alternativamente, en propiltiosulfonato de propilo.

Cytotoxicity mediation of cells evidencing surface expression of TROP-2

This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

Cytotoxicity mediation of cells evidencing surface expression of TROP-2

This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

Cytotoxicity mediation of cells evidencing surface expression of TROP-2

The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders

Disclosed herein are thermoreverisble gel compositions containing a multiparticulate glutamate receptor antagonist, and methods for the treatment of otic diseases or conditions through intratympanic administration of the composition to an individual afflicted with an otic disease or condition.

Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders

Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with auris sensory cell modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders

Disclosed herein are auris acceptable gel compositions containing a multiparticulate glutamate receptor antagonist, and methods for the treatment of otic diseases or conditions through intratympanic administration of the composition to an individual afflicted with an otic disease or condition.

Routing clip elements with a living hinge and interlocking closure

A modular system of routing clip subcomponents having compatible interlocking features allows for as-needed assembly of multiple clips and extensions, thereby eliminating the need for specialized standoff brackets and clipping devices when routing vehicle wires, hoses, tubes, cables, harnesses, and the like. Generally molded from high-impact and decay resistant polymers, the elements of the modular system are inexpensive to manufacture and simple to assemble by hand.

A delivery apparatus for a self-expanding stent

In accordance with the present invention, there is provided a delivery apparatus for a self-expanding stent. The apparatus has an outer sheath forming an elongated tubular member having distal and proximal ends and an inside and outside diameter. The apparatus also includes an inner shaft located coaxially within the outer sheath. The inner shaft has a distal end, a proximal end and a longitudinal axis extending therebetween. At least a portion of the inner shaft is made from a flexible coiled member. The shaft preferably includes a stop attached thereto, the stop being proximal to the distal end of the sheath. Lastly, the apparatus includes a self-expanding stent located within the outer sheath, wherein the stent makes frictional contact with the outer sheath and the shaft is disposed coaxially within a lumen of the stent. During deployment of the stent, the stent makes contact with the stop.

A segmented tissue-to-tissue anchoring device and method of using the same

The invention describes an apparatus and method of use for anchoring two or more body tissue layers to one another. The apparatus includes a plurality of individual anchor segments (28) that are placeable within a body cavity. The segments may assume a first relaxed state wherein the segments are movable relative to each other and alignable along an initial longitudinal axis (20) for initial placement of the apparatus through the body tissue layers. Once placed within the body cavity, the anchor segments are manipulated into a second rigid state with an actuator wherein the.segments assume a rigid configuration at a transverse angle relative to the initial longitudinal axis.

ELECTRONIC BALLAST FOR DISCHARGE LAMPS

L'INVENTION CONCERNE L'ECLAIRAGE. UN BALLAST ELECTRONIQUE POUR LAMPES A DECHARGE COMPREND NOTAMMENT UN TRANSFORMATEUR DE PUISSANCE T2, UN TRANSFORMATEUR AUXILIAIRE T3 DONT LES ENROULEMENTS SECONDAIRES ALIMENTENT LES FILAMENTS DE CATHODE RESPECTIFS DES LAMPES, UN TRANSFORMATEUR DE REACTION T1 ET UN ONDULEUR 20 QUI FAIT CIRCULER DES IMPULSIONS DE COURANT DE SENS ALTERNES DANS LE TRANSFORMATEUR DE PUISSANCE, SANS SATURER CE DERNIER. SEUL LE TRANSFORMATEUR DE REACTION SE SATURE POUR DEFINIR CHAQUE DEMI-CYCLE DE FONCTIONNEMENT. APPLICATION A L'ECLAIRAGE DES LOCAUX COMMERCIAUX. THE INVENTION CONCERNS LIGHTING. AN ELECTRONIC BALLAST FOR DISCHARGE LAMPS INCLUDES IN PARTICULAR A T2 POWER TRANSFORMER, A T3 AUXILIARY TRANSFORMER WHOSE SECONDARY WINDINGS SUPPLY THE CATHODE FILAMENTS RESPECTIVE OF THE LAMPS, A T1 REACTION TRANSFORMER AND A 20 CURRENT SOURCE INVERTER ALTERNATE IN THE POWER TRANSFORMER, WITHOUT SATURIZING THIS LATEST. ONLY THE REACTION TRANSFORMER IS SATURATED TO DEFINE EACH HALF-CYCLE OF OPERATION. APPLICATION TO THE LIGHTING OF COMMERCIAL PREMISES.

Stabilized preparations for use in nebulizers

Stabilized dispersions are provided for the delivery of a bioactive agent to the respiratory tract of a patient. The dispersions preferably comprise a stabilized colloidal system which may comprise a fluorochemical component. In particularly preferred embodiments, the stabilized dispersions comprises perforated microstructures dispersed in a fluorochemical suspension medium. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as by settling or flocculation. In particularly preferred embodiments, the stabilized dispersions may be administered to the lung of a patient using a nebulizer.

Methods for recovering metals from electronic waste, and related systems

A method of recovering metals from electronic waste comprises providing a powder comprising electronic waste in at least a first reactor and a second reactor and providing an electrolyte comprising at least ferric ions in an electrochemical cell. The method further includes contacting the powders within the first reactor and the second reactor with the electrolyte to dissolve at least one base metal from each reactor into the electrolyte and reduce at least some of the ferric ions to ferrous ions. The ferrous ions are oxidized at an anode of the electrochemical cell to regenerate the ferric ions. The powder within the second reactor comprises a higher weight percent of the at least one base metal than the powder in the first reactor. Additional methods of recovering metals from electronic waste are also described, as well as an apparatus of recovering metals from electronic waste.

Auris formulations for treating otic diseases and conditions

Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders

Disclosed herein are compositions and methods for the treatment of otic disorders with apoptosis modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).

Reverse fluorocarbon emulsion compositions for drug delivery

A polar liquid-in-perfluorochemical emulsion or microemulsion for use in delivery of therapeutic or diagnostic agents. These compositions are formed by combining a discontinuous aqueous phase, a continuous fluorocarbon phase and a nonfluorinated surfactant. Further, the polar liquid-in-fluorochemical emulsions may be used to form multiple emulsions having an aqueous continuous phase. Such emulsions and microemulsions are suitable for the administration of pharmaceutical agents including genetic material.

Polymer blends and their application as viscosity index improvers

The present invention relates to a polymer blend containing a high ethylene content ethylene-propylene copolymer and a lower ethylene content ethylene-propylene copolymer. The polymer blend of the present invention is useful for the preparation of viscosity index improvers with improved lower temperature properties relative to conventional viscosity index improvers.

Methods, systems, and devices for improved sensors for continuous glucose monitoring

Methods, systems, and devices for continuous glucose monitoring. More particularly, the methods, systems, and devices describe a working electrode with a GOx sensor and a background electrode in which the background electrode has no GOx sensor. The system may then compare the first signal and the second signal to detect ingestion of a medication by the user. The system may generate a sensor glucose value based on the comparison.

Continuous fluorochemical microdispersions for delivery of pharmaceutical agents

Semiconductor-solid state laser optical waveguide pump device and method

The invention includes a solid state laser (22) which outputs wavelength emission .lambda.ss centered about 946 nm, combined with a lasering waveguide (24) which includes a Yb doped optical waveguide (26) such that when the .lambda.ss output is inputted into the lasing waveguide (24) the lasing waveguide produces a wavelength emission .lambda.y centered about 980 nm. The invention further includes the utilization of pump light with optical waveguide amplifying device.

Multi-participant audio/video communication system with participant role indicator

An audio/video communication system displays the status of participants in a video chat session. The system includes multiple video chat capable (VCC) information handling systems (IHSs) that display video images of the participants. In this manner, each user may see the user's own video image as well as the video images of other users in the video chat session. When a user speaks, that user's VCC IHS detects audio, thus designating a speaker participant. This user's VCC IHS includes a gaze direction detector that determines at which particular user video image the user gazes, thus determining a target participant. The VCC IHS sends speaker participant ID information and target participant ID information to other VCC IHSs in the video chat session. In response, the other VCC IHSs display an indicator that designates one user video image as the speaker participant and another user video image as the target participant.

Flexible member for angled system

Disclosed is an instrument that may an interior tube and an external tube. The exterior tube may be fixed relative to an interior tube, where the interior tube may rotate or oscillate relative to the exterior tube. Further, the two tubes may be co-bent such that an angle is formed by both of the tubes.

Engineered particles and methods of use

Engineered particles are provided may be used for the delivery of a bioactive agent to the respiratory tract of a patient. The particles may be used in the form of dry powders or in the form of stabilized dispersions comprising a nonaqueous continuous phase. In particularly preferred embodiments the particles may be used in conjunction with an inhalation device such as a dry powder inhaler, metered dose inhaler or a nebulizer.

Tapered fiber laser

A tapered fiber laser having a multi-mode section, a single-mode section, and either a tapered section or fundamental mode matching junction therebetween. The multi-mode section has a large core to directly receive pump light from a broad stripe laser or diode bar, and a length preferably longer than the absorption length of the pump light (so optical amplification occurs predominantly in the multi-mode section). Doping levels can be increased to reduce the multi-mode length. The taper angle is sufficiently small to produce adiabatic compression of the fundamental mode from the multi-mode to single-mode sections, and acts as a cutoff filter favoring lasing of the fundamental mode within the multi-mode section. Alternately, the step junction may have a mode field diameter matched to the lowest-order mode, with laser light output via the single-mode section. The invention can be applied to waveguides (particularly those having an aspect ratio corresponding to a broad stripe laser source), doped with ytterbium or neodymium ions, and is particularly advantageous as a pump source for an erbium-doped fiber amplifier (EDFA).

Controlled-release CNS modulating compositions and methods for the treatment of otic disorders

Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).

Cytotoxicity mediation of cells evidencing surface expression of TROP-2

The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

Controlled release corticosteroid compositions and methods for the treatment of otic disorders

Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders

Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with auris sensory cell modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Intracavity frequency-converted optically-pumped semiconductor laser

An intracavity, frequency-doubled, external-cavity, optically-pumped semiconductor laser in accordance with the present invention includes a monolithic surface-emitting semiconductor layer structure including a Bragg mirror portion and a gain portion. An external mirror and the Bragg-mirror portion define a laser resonant-cavity including the gain-portion of the semiconductor layer structure. A birefringent filter is located in the resonant-cavity for selecting a frequency of the laser-radiation within a gain bandwidth characteristic of semiconductor structure. An optically-nonlinear crystal is located in the resonant-cavity between the birefringent filter and the external mirror and arranged to double the selected frequency of laser-radiation.

Self-expanding stent implant

Stabilized preparations for use in metered dose inhalers

Stabilized dispersions are provided for the delivery of a bioactive agent to the respiratory tract of a patient. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a hydrofluoroalkane propellant. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as, by settling or flocculation. In particularly preferred embodiments, the stabilized dispersions may be administered to the lung of a patient using a metered dose inhaler.

Flexible member for angled system

Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders

Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with auris sensory cell modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Radiopaque intraluminal medical device

A stent or other intraluminal medical device having markers formed from housings integral with the stent and marker inserts having a higher radiopacity than the stent provides for more precise placement and post-procedural visualization in a vessel, by increasing the radiopacity of the stent under X-ray fluoroscopy. The housings are formed integral to the stent and the marker inserts are made from a material close in the galvanic series to the stent material and sized to substantially minimize the effect of galvanic corrosion.

Variable focus optical system

A variable focus optical system is particularly suitable for use in acquiring digital images for subsequent processing in a hand held, omnidirectional symbology or bar code reader (12) by which linear and two dimensional (matrix, maxi-code) bar codes (28; 34; 40; 52; 54) may be imaged over relatively long working distances. The imaging system includes a focusing objective taking lens (92) and a two-dimensional photodetector (93) that operate to form an image of an object such as a bar code in X and Y directions simultaneously and generates an electrical signal representative of the object or code for subsequent downstream processing. Focusing is achieved via a rotating disk (94) that carries a plurality of optical shims (130) or other light controlling surfaces to provide for different focus zones. A through-the-lens (TTL) targeting system is provided to visually assist the user in positioning the system for a variety of objects to assure that an object will be captured within the field of view and be sharply imaged on the photodetector (93) when the lens (92) is focused. Two different forms of artificial illumination are provided to accommodate nearby objects that may be either specular or partially diffuse and more distant objects where the reflection characteristics have less impact on image contrast. Ranging through the lens (92) using elements of the photodetector (93) is included to provide information to set the focus of the objective lens (92) in one of many possible focusing zones.

Aircraft skin attachment system

A method for forming a structural member and a structural member produced thereby includes positioning a first composite section and a second composite section within a tool. The tool has an inner surface and a wall intersection and is supported by a tool platform. The tool platform and a pressure platform are relatively movable between an open position and a closed position. The tool has a non-planar outer surface against which the member may be pressed. A composite splice member is positioned at least partially overlapping both the first composite section and the second composite section to form a joint in the composite structural member. The composite structural member is pressed against the non-planar outer surface of the tool by applying pressure to the joint from a pressure bladder. Heat is applied to the composite structural member at the joint to cure the composite splice member to the first composite section and the second composite section.

Flexible member for angled system

Disclosed is an instrument that may an interior tube and an external tube. The exterior tube may be fixed relative to an interior tube, where the interior tube may rotate or oscillate relative to the exterior tube. Further, the two tubes may be co-bent such that an angle is formed by both of the tubes.

Rare earth doped optical fiber

An optical fiber including: (i) a silica based, Yb doped core having a first index of refraction nj, said core comprising more than lwt % of Yb, said core having less than 5 dB/km loss at a wavelength situated between 1150 run and 1350 nm and less than 20 dB/km loss at the wavelength of 1380 nm and slope efficiency of over 0.8; and (ii) at least one silica based cladding surrounding the core and having a second index of refraction n2, such that n\> n2.

Laser illuminated projection displays

A projection video display includes a light source including an OPS-laser delivering laser radiation in multiple transverse modes (a multiple-transverse-mode OPS-­laser). The display includes a spatial light modulator for spatially modulating the radiation from the multiple-transverse-mode OPS-laser in accordance with a portion of an image to be displayed. Projection optics project the spatially modulated light on a screen on which the image is to be displayed. In one example the OPS-laser is a diode-laser array pumped OPS-laser and is one of three lasers, one delivering red light, one delivering blue light, and the other delivering green light. The lasers are time modulated such that the spatial light modulator receives light from each of the lasers separately. The OPS laser is directly time modulated by periodically turning the diode-laser array on and off.

auricular formulations for the treatment of diseases and conditions of the ear

FORMULAÇÕES AURICULARES PARA O TRATAMENTO DE DOENÇAS E CONDIÇÕES DO OUVIDO São aqui reveladas composições e métodos para o tratamento de distúrbios auriculares com agente imunomoduladores e moduladores da pressão auricular. Nesses métodos, as composições e formulações auriculares são administradas de forma local a um indivíduo que sofre de um distúrbio auricular, através da aplicação direta das composições e formulações imunomoduladoras e/ou moduladoras da pressão auricular no ouvido médio e/ou áreas do ouvido interno, ou por meio de perfusão no ouvido médio e/ou estruturas do ouvido interno. AURICULAR FORMULATIONS FOR THE TREATMENT OF DISEASES AND HEARING CONDITIONS Here are revealed compositions and methods for treatment of auricular disorders with agent immunomodulators and atrial pressure modulators. In these methods, auricular compositions and formulations are administered locally to an individual suffering from a auricular disorder, through the direct application of immunomodulating and / or modulating compositions and formulations of atrial pressure in the middle ear and / or areas of the ear internal, or through perfusion in the middle ear and / or inner ear structures.

A surface-mount multi-layer electrical circuit protection device with an active element between PPTC layers

There is disclosed an electrical circuit for connection between an electrical energy source and an electrical load, the circuit being formed on a circuit substrate and having at least one surface-mounted electrical circuit protection device. The surface-mounted electrical circuit protection device comprises a first polymeric positive temperature coefficient resistive ("PPTC") element and a second PPTC element; and at least one heat-generating electrical component positioned between the first and second PPTC elements and in effective thermal contact such that an electrical current above a threshold level passing through the component causes the component to heat, the heat being transferred to the PPTC elements and increasing the resistance of the first or second PPTC elements. A method for making the circuit protection device is also disclosed.

Quasi-CW UV laser with low peak pulse-power

Laser apparatus is disclosed in which fundamental-wavelength optical pulses delivered from a mode-locked laser resonator at a pulse-repetition frequency (PRF) are converted to harmonic-wavelength pulses in an optical delay loop. One example is disclosed in which the harmonic-wavelength pulses are delivered directly from the delay loop. Another example is disclosed in which the harmonic-wavelength pulses are divided by the delay loop into a number of temporally spaced-apart replicas thereof, and the delay loop delivers bursts of replicas of different one of the harmonic wavelength pulses at a burst-repetition frequency equal to or a multiple of the PRF of the resonator.

A delivery apparatus for a self-expanding stent

Perforated microparticles and method of use thereof

Optical fiber with birefringence and large mode field diameter

Single-dose, ready-to-use injectable formulations

Provided are single-dose, ready-to-use formulations and methods for preparing the formulations that include a compound of Formula (I) including pharmaceutically acceptable salts and amorphous and polymorph forms thereof.

Methods and Devices for Rapid Measurement of Visual Sensitivity

The present invention relates to methods for efficient adaptive measurement and classification of contrast sensitivity functions and spatiotemporal contrast sensitivity surface by selecting the most informative stimulus before each trial. Also disclosed are devices for implementing such methods.

COATED MEDICAL EQUIPMENT

Phospholipid-based powders for drug delivery

Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.

Methods and systems for the electrochemical reduction of carbon dioxide using switchable polarity materials

A method of electrochemically reducing CO2 comprises introducing a first feed stream comprising H2O to a positive electrode of an electrolysis cell comprising the positive electrode, a negative electrode, and a proton conducting membrane. A second feed stream comprising a solvent and a non polar form of a switchable polarity material is directed into a CO2 capture apparatus. A third feed stream comprising CO2 is directed into the CO2 capture apparatus to interact with the second feed stream and form a first product stream comprising the solvent and a polar form of the switchable polarity material. The first product stream is introduced to the negative electrode. A potential difference is applied between the positive electrode and the negative electrode to convert the polar form of the switchable polarity material into CO2 and the non-polar form and to form products from the CO2 and the solvent. A CO2 treatment system is also described.

Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders

Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Alzheimer's disease secretase

"SECRETASE DE DOENçA DE ALZHEIMER". A presente invenção provê a enzima e procedimentos enzimáticos para clivar o sítio de clivagem de secretase <225> da proteína APP e ácidos nucléicos associados, peptídeos, vetores, células e ensaios e isolados de células.

Optical fiber with birefringence and large mode field diameter

According to the present invention the optical fiber includes a core with a first refractive index (n 1 ) and the innermost core region with the refractive index n 0 , a cladding surrounding the core, the cladding having a third refractive index (n 3 ), wherein n 1 >n 3 and n 0 <n 1 . According to some of the embodiments the optical fiber may also include a moat surrounding and abutting the core and situated between the core and the cladding, the moat having a second refractive index (n 2 ), wherein n 3 >n 2 . It is preferable that at least one of the core, innermost core region and/or moat has a non-circular shape.